A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase 1 Terminated 41 enrolled Calithera Biosciences, Inc

Non-randomizedSequentialOpen-labelOther

Summary

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.

Timeline

Start: 2016-08-12
Primary completion: 2018-11-30
Completion: 2018-11-30

Publications

Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Janez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jimenez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	240 mg	Intravenous
Subject	mivavotinib	Small molecule	60 mg	Oral
Subject	mivavotinib	Small molecule	80 mg	Oral
Subject	mivavotinib	Small molecule	100 mg	Oral

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications